01

Krystal Biotech Reports KB113 Lesion Regression Data in Gorlin Syndrome

Krystal Biotech reports KB113, a topical gene therapy candidate, drove lesion regression in Gorlin syndrome patients — an early signal in basal cell nevus syndrome care.